Liaoning Chengda Biotechnology Co. Ltd. A
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company's rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant h… Read more
Liaoning Chengda Biotechnology Co. Ltd. A (688739) - Total Liabilities
Latest total liabilities as of June 2025: CN¥431.10 Million CNY
Based on the latest financial reports, Liaoning Chengda Biotechnology Co. Ltd. A (688739) has total liabilities worth CN¥431.10 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Liaoning Chengda Biotechnology Co. Ltd. A - Total Liabilities Trend (2019–2024)
This chart illustrates how Liaoning Chengda Biotechnology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Liaoning Chengda Biotechnology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Liaoning Chengda Biotechnology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Heritage Insurance Hldgs Inc
NYSE:HRTG
|
USA | $1.93 Billion |
|
Arvinas Inc
NASDAQ:ARVN
|
USA | $284.00 Million |
|
Puyang Refractories Group Co Ltd
SHE:002225
|
China | CN¥4.74 Billion |
|
Sercomm Corp
TW:5388
|
Taiwan | NT$32.01 Billion |
|
GCS Holdings
TWO:4991
|
Taiwan | NT$521.28 Million |
|
WEB Travel Group Ltd
AU:WEB
|
Australia | AU$1.10 Billion |
|
Power HF Co Ltd
SHG:605100
|
China | CN¥455.28 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Liaoning Chengda Biotechnology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 21.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liaoning Chengda Biotechnology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liaoning Chengda Biotechnology Co. Ltd. A (2019–2024)
The table below shows the annual total liabilities of Liaoning Chengda Biotechnology Co. Ltd. A from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥489.12 Million | +1.43% |
| 2023-12-31 | CN¥482.23 Million | +18.73% |
| 2022-12-31 | CN¥406.16 Million | -7.84% |
| 2021-12-31 | CN¥440.72 Million | +13.09% |
| 2020-12-31 | CN¥389.70 Million | +25.41% |
| 2019-12-31 | CN¥310.75 Million | -- |